Enanta Pharmaceuticals (ENTA) Financials

$12.29

$-0.83 (-6.33%)

As on 15-Sep-2026 16:00EDT

Market cap

$377 Mln

Revenue (TTM)

$65 Mln

P/E Ratio

--

P/B Ratio

3.7

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18	Sep-17	Sep-16
Operating Revenue	65.26	65.32	67.64	79.20	86.16	97.07
Cost of Revenue	3.70	4.59	--	2.37	2.97	--
Gross Profit	64.05	60.74	67.64	79.20	86.16	97.07
Operating Expenses	122.78	146.09	189.33	216.41	210.00	206.65
Operating Profit (EBIT)	-58.73	-85.35	-121.69	-137.21	-123.84	-109.57
Other Income	--	--	--	--	0.08	-0.03
Profit before Tax	-63.13	-83.55	-117.79	-131.00	-122.19	-107.58
Provision for Tax	0.10	-1.66	-1.74	2.82	-0.43	-28.58
Profit after Tax (Net Income)	-63.23	-81.89	-116.05	-133.82	-121.76	-79.00
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-121.76	-79.00

Liabilities ($ Mln)	TTM	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18	Sep-17	Sep-16
Shareholder's Funds	101.07	64.72	128.81	216.74	321.33	399.43
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	141.64	167.46	190.30	182.75	29.43	5.26
Current Liabilities	54.17	48.56	57.54	62.79	29.83	36.17
Total Liabilities	351.04	280.73	376.65	462.28	380.59	440.86

Assets ($ Mln)	TTM	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18	Sep-17	Sep-16
Non-Current Assets	93.25	76.40	76.80	39.48	68.88	121.84
Current Assets	203.62	204.34	299.85	422.79	311.71	319.02
Total Assets	351.04	280.73	376.65	462.28	380.59	440.86
Total Debt*	55.66	201.06	226.06	26.51	26.69	6.84
Net Current Assets	149.45	155.78	242.32	360.00	281.89	282.85

Cashflow ($ Mln)	TTM	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18	Sep-17	Sep-16
Cash From Operating Activities	--	-19.27	-78.76	-103.15	-84.78	-70.00
Cash Flow from Investing Activities	--	40.35	58.24	-53.58	54.90	36.99
Cash from Financing Activities	--	-26.62	-27.63	198.13	20.03	3.08
Net Cash Inflow / Outflow	--	--	--	--	-9.85	-29.93

Financials Ratios	TTM	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18	Sep-17	Sep-16
Adjusted EPS ($)	-2.41	-3.83	-5.48	-6.35	-5.91	-3.91
Cash EPS ($)	--	-3.62	-5.37	-6.24	-5.77	-3.74
Adjusted Book Value ($)	--	3.03	6.08	10.29	15.60	19.75
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.90	-3.72	-4.90	-4.12	-3.46
Free Cash Flow per Share ($)	--	-1.50	-4.56	-5.33	-4.22	-3.50

Profitability Ratios	TTM	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18	Sep-17	Sep-16
ROCE (%)	--	-26.39	-38.80	-45.26	-32.28	-18.13
ROE (%)	-55.55	-84.63	-67.17	-49.74	-33.79	-18.48
ROA (%)	-18.15	-24.91	-27.67	-31.75	-29.64	-16.96
EBIT Margin (%)	-109.42	-116.14	-157.98	-158.89	-141.82	-112.88
Net Margin (%)	-96.89	-125.36	-171.58	-168.95	-141.18	-81.40
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18	Sep-17	Sep-16
Revenue Growth (%)	0.70	-0.03	-0.15	-0.08	-0.11	-0.21
EBIT Growth (%)	17.15	28.99	15.10	-2.99	-11.51	-163.15
Net Profit Growth (%)	31.28	29.43	13.28	-9.91	-54.13	-118.41
EPS Growth (%)	44.27	0.30	0.14	-0.08	-0.51	-1.17
Book Value Growth (%)	-6.56	--	--	--	--	--

Valuation Ratios	TTM	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18	Sep-17	Sep-16
Price / Earnings	--	-3.13	-1.89	-1.76	-8.78	-14.54
Price / Book Value	3.67	3.95	1.70	1.09	3.33	2.88
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	41.13	-3.79	-1.89	0.88	-7.10	-8.58
Close Price ($)	14.58	11.97	10.36	11.17	51.87	56.81
High Price ($)	17.15	15.34	17.80	62.06	102.00	59.23
Low Price ($)	6.44	4.09	8.08	11.03	37.59	40.32
Market Cap ($ Cr)	377.47	--	--	--	--	--

Solvency Ratios	TTM	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18	Sep-17	Sep-16
Debt to Equity	--	3.11	1.75	0.12	0.08	0.02
Short term debt to equity ratio	0.04	0.52	0.28	0.02	0.01	0.01
Current Ratio	3.76	4.21	5.21	6.73	10.45	8.82
Quick Ratio	3.76	--	--	--	--	9.85
Interest Coverage	-3.89	-9.88	-9.77	-24.45	-77.68	-20.57

Operating Efficiency Ratios	TTM	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18	Sep-17	Sep-16
Debtors to sales (%)	10.01	10.54	57.14	50.02	56.91	62.66
Asset Turnover	0.19	0.20	0.16	0.19	0.21	0.21
Receivable days	--	127.28	211.32	204.41	232.87	158.64
Inventory Days	--	--	--	--	-4,576.99	--
Payable days	--	396.23	--	777.72	954.59	--
Cash Conversion Cycle	--	--	--	--	-5,298.70	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.